Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with an advanced or spreading cancer that has either stopped responding to existing treatments, has continued to grow despite standard treatment, or where existing treatments have caused intolerable side effects.
- People whose cancer has tumors that can be measured or evaluated through standard imaging or laboratory tests.
- People who have an adequate level of physical functioning, as measured by a standard medical scale called the ECOG performance status (confirm with trial site for the specific score required).
- People who are 18 years of age or older.
- People whose cancer either has a specific genetic change called a RAS mutation (regardless of cancer type), or who have a type of brain cancer called glioblastoma (with or without a RAS mutation).
Who may not be able to join:
- People who are currently receiving cancer treatment at the time of enrolling in the trial.
- People who have a clinically significant disease or condition affecting a major organ system.
- People who have significant heart or cardiovascular disease, or certain abnormalities on a heart tracing test (ECG).
- People with a known condition called Gilbert's disease, which affects how the liver processes certain substances.
- People who have had a separate, different cancer within the past two years, or who currently have another cancer alongside the target cancer.
- People who experience recurring episodes of low potassium levels in the blood.
- People who are already experiencing nausea, vomiting, or diarrhea at a certain level of severity before the trial begins.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael Mann, MD, RasCal Therapeutics, Inc.
Phone: 310-498-7171
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Maximum Tolerated Dose (MTD) for RSC-1255 as monotherapy; Recommended Phase 2 Dose (RP2D) for RSC-1255 as monotherapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.